2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Genomics, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

248 Azacitidine and venetoclax in patients with higher-risk chronic myelomonocytic leukemia: Results from a prospective, multicenter phase II study with safety run-in.

Raphael Itzykson, MD, PhD, Sylvie Chevret2, Delphine Lebon, MD, PhD3, Sylvain Thépot, MD4, Thomas Cluzeau, MD, PhD5, Thibault Comont, MD6, Rudy Birsen, MD, PhD7, Marie-Pierre Gourin, MD8, Aspasia Stamatoulas Bastard, MD9, Sophie Salazar Sr10, Sophie Park, MD PhD11, Stanislas Nimubona12, Mael Heiblig, MD13, Kristell Desseaux14, Arnaud Saint-Lezer, MD15, Jose Torregrosa, MD16, Christophe Willekens, MD17, Marie Robin, MD18, Matthieu Duchmann19, Dorothée Selimoglu-Buet, PhD20, Eric Solary, MD21, Karine Lemarie22, Fatiha Chermat23, Pierre Fenaux Sr, MD24
1 Hôpital Saint-Louis, AP-HP, Paris, France
2 Hôpital Saint-Louis, AP-HP, Paris, France
3 CHU Amiens, Amiens, France
4 CHU Angers, Angers, France
5 CHU Nice, Nice, France
6 CHU Toulouse, Toulouse, France
7 Hôpital Cochin, AP-HP, Paris, France
8 CHU Limoges, Limoges, France
9 Centre Henri Becquerel, Rouen, France
10 CHU Bordeaux, Bordeaux, France
11 CHU Grenoble, Grenoble, France
12 CHU Rennes, Rennes, France
13 Hospices Civils de Lyon, Lyon, France
14 Hôpital Saint-Louis, AP-HP, Paris, France
15 CH Mont-de-Marsan, Mont-de-Marsan, France
16 CHU Poitiers, Poitiers, France
17 Gustave Roussy, Villejuif, France
18 Hôpital Saint-Louis, AP-HP, Paris, France
19 Hôpital Saint-Louis, AP-HP, Paris, France
20 Gustave Roussy, Villejuif, France
21 Gustave Roussy, Villejuif, France
22 Groupe Francophone des Myelodysplasies (GFM), Paris, France
23 Groupe Francophone des Myelodysplasies (GFM), Paris, France
24 Hôpital Saint-Louis, AP-HP, Paris, France

Context. Higher-risk (HR) Chronic Myelomonocytic Leukemia patients (CMML) have unmet medical needs, with short overall survival (OS, median < 24 months) and limited single-agent activity of hypomethylating agents (HMA) compared to hydroxyurea (PMID 36455187). Azacitidine-Venetoclax (AZA-VEN) is a standard of care for AML but has not demonstrated its superiority in MDS. In CMML, HMA-VEN studies have mostly been conducted in single-center or retrospective studies (PMID 40164584, 39533069). We conducted a multicenter, prospective study of AZA-VEN in HMA-naïve, Higher-Risk CMML patients.

 

Methods. The AVENHIR trial (NCT05768711) is a multicenter prospective phase II study with safety run-in. The primary endpoints were pre-specified DLTs (safety run-in) and overall response according to modified 2015 MDS/MPN IWG criteria (PMID  25624319) during the first 6 cycles (phase II). Eligible patients were adult, Higher-Risk (CPSS-mol [PMID  27385790] intermediate-2 [int-2]/high), HMA- and VEN- naïve CMML (WHO 2016 amended to ICC 2022 criteria) patients with ECOG PS 0-1. The designs were 3+3 exploring 2 dose levels (DL) for safety run-in and one-stage Fleming for phase II.

 

Results. Between 10/2023 and 10/2025, 56 patients were screened and 42 enrolled in 15 centers. Four patients were accrued to the safety run-in (1 not assessable for DLTs) at DL1 (AZA 75 mg/m²/d d1-7, VEN ramp-up then 400 mg/d, d1-14, 28d cycles) with no DLT observed. All 38 patients accrued in Phase II were treated at DL1, and the 42 patients (M/F 26/16, median age 72y) grouped in the intent-to-treat (ITT) population. At screening, ICC 2022 was CMML-1/2 in 20/22 cases (48%/52%), CMML-MP and -MD in 27/15 (64%/36%). No oCMML case was enrolled. CPSS-mol was int-2/high in 44%/56% of cases respectively. Median WBC was 16.5 x109/L (IQR, 10;27.5). Spleen was palpable in 8 cases (19%), and median MPN-SAF TSS was 18 (IQR, 8;26). Two patients dropped out before cycle 1 (consent withdrawal, n=1; progression, n=1) but were retained in the ITT population; 30 and 17 completed the pre-planned evaluation visits after 3 and 6 cycles respectively. The median number of cycles received was 3 (IQR, 2;5). Twenty-eight (67%) patients achieved any response across the first 6 cycles. Best response was CR in 10 (25%), CCyR in 1 (2%), marrow response (MR) with clinical benefit (CB) in 4 (10%), MR without CB in 9 (22%) and CB only in 4 (10%). Response persistence ≥12 and 24 months was estimated at 57.4% (95% CI, 34.4-82.2%) and 46.4 (95% CI, 22.9-78.1%). Of 11 patients with available follow-up data 12 months from study exit, 4 proceeded to allogeneic hematopoietic cell transplantation.

With a median follow-up of 11.7 months (IC95 10.1 to 17.2), 13 patients have died and 8 have progressed, relapsed, or transformed to AML. At 24 months, OS is estimated at 37.7% (95%CI 18 to 78.8) and PFS at 31.6% (95%CI 16.7 to 59.8).

Grade 3/4 hematological toxicities occurred in 79% of patients. Median interval between cycles was 31.5 days (IQR, 28;37.5). Six (15%) patients ended the treatment during the first six cycles due to prolonged myelosuppression without morphological evidence of leukemia. Grade 3/4 non-hematological AEs (CTCAE v5) occurred in 20 (48%) patients and febrile neutropenia occurred in 12 (29%) cases. No TLS occurred.

 

Conclusion. We report the first CMML-specific prospective, multicenter study of venetoclax combination to HMAs. In a higher-risk CMML population, combining venetoclax to azacitidine results in significant but manageable hematological toxicity. The response rate and estimated survival are in line with retrospective data. Dedicated studies are required to determine whether addition of venetoclax to HMAs represents an optimal bridge to transplantation. Correlative studies inspecting baseline BCL-2, MCL-1 and BCL-xL protein expression (MAC-Score, PMID 36892565) in baseline bone marrow samples are ongoing to guide treatment selection in this high risk population.

Raphael Itzykson, MD, PhD: Astellas - Honoraria; Abbvie - Honoraria; Servier - Honoraria; Novartis - Honoraria; Jazz - Honoraria; BioMed Valley Discoveries - Research Funding; Advesya - Research Funding; Abbvie - Research Funding; Auron - Research Funding; BMS - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony)